Our earlier studies concentrated on MST1 within the liver, indicating that increased MST1 levels suppressed fat synthesis and enhanced fat oxidation, and proposed diverse materials targeting MST1 for NAFLD treatment, such as microRNA, exosomes, and nanoparticles.33, 34. The gene discussed is MST1; the disease is metabolic dysfunction-associated steatotic liver disease.